Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 mutational status is predictive of pazopanib response in advanced sarcomas.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2016

Koehler K, Liebner D, Chen J L

Abstract excerpt

BACKGROUND: To investigate whether TP53 DNA mutational status impacts progression-free survival (PFS) in patients with advanced sarcomas (soft tissue sarcoma) treated with vascular endothelial growth factor receptors (VEGFR) inhibition. PATIENTS AND METHODS: We retrospectively reviewed 19 cases of patients treated at the Ohio State James Comprehensive Cancer Center with advanced sarcoma treated with VEGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Pyrimidines

Share to Receptors, Vascular Endothelial Growth Factor

Share to Retinoblastoma Protein

Share to Sarcoma

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 26646755
DOI: 10.1093/annonc/mdv598
PMCID: PMC5006122

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutational status is predictive of pazopanib response in advanced sarcomas.PMID 26646755Read ↗

TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.Semantic proximity Read ↗

P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.Semantic proximity Read ↗

Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation.Semantic proximity Read ↗

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanibSemantic proximity Read ↗

TP53 Mutations as a Driver of Metastasis Signaling in Advanced Cancer PatientsSemantic proximity Read ↗

p53 as a Potential Actionable Target in Myxofibrosarcoma: A Molecular and Pathologic Review of a Single-Institute Series.Semantic proximity Read ↗

Molecular biomarkers impact survival after neoadjuvant chemoradiation in locally advanced soft tissue sarcoma patientsSemantic proximity Read ↗

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.Semantic proximity Read ↗

Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies.Semantic proximity Read ↗

Clinical impact of TP53 mutation status on survival outcomes in metastatic colorectal cancer.Semantic proximity Read ↗

Targeted treatment of soft-tissue sarcomaSemantic proximity Read ↗

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.